BioNTech's cancer drug meets primary endpoint in Phase 2 trial

By Yahoo! Finance | Jul 30, 2024 at 06:55 AM EST

BioNTech's cancer drug candidate BNT111 showed promising results in a Phase 2 trial for advanced melanoma patients, with a significant improvement in response rates when combined with a checkpoint inhibitor. The company is shifting focus to cancer drug development amid declining COVID-19 vaccine sales.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.